CONJUGATED PEPTIDES, IMMUNOLOGICAL REAGENT CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS

摘要

A heteroconjugate is formed by linking a T cell binding ligand (TCBL) such as Peptide J of β-2 microglobulin to a modified HGP-30 antigenic peptide fragment of p17 gag peptide, such as, for example (I). The heteroconjugate is effective in eliciting a TH1 directed immune response and provides a vaccine composition for treating or preventing AIDS.